Dose fentanyl formulations in randomised controlled studies
| Formulations | Dose fentanyl | Comparator dose | Reference | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 50 | 100 | 200 | 400 | 600 | 800 | 1200 | 1600 | |||
| OTFC Nasal spray | − 23 | − 32 | 34 40 | 30 − | 11 − | 5 − | 5 − | 5 − | NA | 59 |
| FPNSNasal spray | Pectin: 328 µg Nasal: 165 µg | 60 | ||||||||
| SLF Placebo | 4 | 6 | 7 16 (300 µg) | 8 | 21 | 61 | ||||
| SLF Placebo | 26% | 21% | 10% 26% (300 mg) | 5% | 2% | 62 | ||||
| SLF IRMS oral | Mean dose 235 µg | Mor: 38 mg | 63 | |||||||
| SLF-E Placebo | 36% (133 µg)) | 31% (267 µg) | 14% | 13% (567 µg) | 6% | 64 | ||||
| OTFC IRMS oral | 10% | 19% | 25% | 15% | 17% | 15% | 15 mg: 27% 30 mg: 46% 45 mg: 17% 60 mg: 10% | 65 | ||
| OTFC Mor IV | 24% | 12% | 20% | 4% | 32% | 8% | Fixed ratio: 200/4, etc | 66 | ||
| OTFC Placebo | No data | No data | No data | No data | No data | No data | No data | No data | NA | 67 |
| Buccal Placebo | 12 | 11 | 20 | 10 | 24 | NA | 68 | |||
| Buccal Placebo | 8% | 12% | 18% | 28% | 34% | NA | 69 | |||
| Buccal Placebo | 7% | 14% | 19% | 17% | 11% | 6% | 27% dose not known | NA | 70 | |
| Buccal film Placebo | 5% | 19% | 28% | 24% | 25% | NA | 71 | |||
| Nasal spray Placebo | 18 | 48 | 45 | NA | 72 | |||||
| FPNS IRMS oral | 16 | 18 | 30 | 15 | Mor: 29 mg | 73 | ||||
| FPNS IRMS oral | Pectin: 182 µg Mor: 17 mg | 74 | ||||||||
| FPNS Placebo | 11% | 10% | 33% | 47% | 75 |
FPNS, fentanyl pectin nasal spray; IRMS, immediate release morphine sulfate; IV, intravenous; Mor, morphine; NA, not applicable; Nasal, fentanyl nasal spray; OTFC oral transmucosal fentanyl citrate; SLF, sublingual fentanyl (Abstral) ; SLF-E, sublingual fentanyl ethypharm (Recivit).